Citius Oncology (CTOR) Times Interest Earned (2025 - 2026)

Citius Oncology (CTOR) recorded quarterly Times Interest Earned of -$1.69 in Q1 2026, down 491.94% quarter-over-quarter from -$0.29 in Q4 2025.

Citius Oncology (CTOR) Times Interest Earned (2025 - 2026) Analysis & Trends

Citius Oncology's Times Interest Earned history runs 2 years deep, the most recent figure standing at -$1.69 for Q1 2026.

In Q1 2026, Times Interest Earned changed N/A year-over-year to -$1.69; the TTM figure through Mar 2026 stood at -$2.57 (changed N/A YoY), while the FY2025 annual figure was -$1.17, changed N/A from the prior year.
Times Interest Earned was -$1.69 for Q1 2026 at Citius Oncology, down from -$0.29 in the prior quarter.
In the past five years, Times Interest Earned ranged from a high of -$0.29 in Q4 2025 to a low of -$82.26 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Times Interest Earned (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	-
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	13.44
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	108.60
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	5.39
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	-2.31
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	16.72
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	Citius Oncology	75.12 Mn	72.49 Mn	1.34 Mn	-1.69

Download Data